bosentan anhydrous has been researched along with Hypertrophy, Right Ventricular in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bresser, P; Kloek, JJ; Marcus, JT; Reesink, HJ; Surie, S; van der Plas, MN; Vonk-Noordegraaf, A | 1 |
| Bauer, Y; Bortolamiol, C; Cattaneo, C; Clozel, M; Delahaye, S; Freti, D; Hadana, H; Hess, P; Iglarz, M; Landskroner, K; Nayler, O; Renault, B; Rey, M; Schläpfer, M; Steiner, P; Studer, R; Vercauteren, M; Vezzali, E; Wanner, D; Weber, E; Whitby, BR | 1 |
| He, JG; Tan, XY | 1 |
| Arzt, M; Blumberg, F; Nüchterlein, M; Pfeifer, M; Schroll, S; Sebah, D | 1 |
| de Boer, MA; Mouchaers, KT; Postmus, PE; Schalij, I; van der Laarse, WJ; van Hinsbergh, VW; van Nieuw Amerongen, GP; Vonk Noordegraaf, A | 1 |
| Choudhary, G; Harrington, EO; Klinger, JR; Martin, D; Troncales, F | 1 |
| Barst, R; Channick, R; Dujardin, K; Espinola-Zavaleta, N; Fourme, T; Frantz, R; Galiè, N; Hinderliter, AL; Kronenberg, A; Kurzyna, M; Leconte, I; Manes, A; Nagueh, SF; Pulido, T; Rainisio, M; Rocchi, G; Rubin, L; Simonneau, G; Torbicki, A | 1 |
| Hill, NS; Klinger, JR; Pietras, L; Warburton, RR | 1 |
2 trial(s) available for bosentan anhydrous and Hypertrophy, Right Ventricular
| Article | Year |
|---|---|
Bosentan treatment is associated with improvement of right ventricular function and remodeling in chronic thromboembolic pulmonary hypertension.
Topics: Aged; Antihypertensive Agents; Bosentan; Endarterectomy; Exercise Test; Exercise Tolerance; Female; Humans; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Magnetic Resonance Imaging; Male; Middle Aged; Netherlands; Pilot Projects; Pulmonary Embolism; Recovery of Function; Single-Blind Method; Sulfonamides; Time Factors; Treatment Outcome; Ventricular Dysfunction, Right; Ventricular Function, Left; Ventricular Function, Right; Ventricular Remodeling; Waiting Lists | 2013 |
Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension.
Topics: Administration, Oral; Adult; Aged; Antihypertensive Agents; Bosentan; Echocardiography, Doppler; Female; Humans; Hypertension, Pulmonary; Hypertrophy, Left Ventricular; Hypertrophy, Right Ventricular; Male; Middle Aged; Sulfonamides; Ventricular Function, Left; Ventricular Function, Right | 2003 |
6 other study(ies) available for bosentan anhydrous and Hypertrophy, Right Ventricular
| Article | Year |
|---|---|
Comparison of Macitentan and Bosentan on Right Ventricular Remodeling in a Rat Model of Non-vasoreactive Pulmonary Hypertension.
Topics: Animals; Bleomycin; Bosentan; Disease Models, Animal; Endothelin Receptor Antagonists; Gene Expression Regulation; Heart Ventricles; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Male; Pulmonary Artery; Pyrimidines; Rats, Wistar; Sulfonamides; Time Factors; Vascular Remodeling; Ventricular Function, Right; Ventricular Remodeling | 2015 |
The remodeling of connexin in the hypertrophied right ventricular in pulmonary arterial hypertension and the effect of a dual ET receptor antagonist (bosentan).
Topics: Animals; Bosentan; Connexin 43; Disease Models, Animal; Endothelin Receptor Antagonists; Gap Junctions; Hemodynamics; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Male; Microscopy, Confocal; Microscopy, Electron; Monocrotaline; Myocytes, Cardiac; Rats; Rats, Sprague-Dawley; Sulfonamides; Ventricular Remodeling | 2009 |
Improvement of bleomycin-induced pulmonary hypertension and pulmonary fibrosis by the endothelin receptor antagonist Bosentan.
Topics: Analysis of Variance; Animals; Antibiotics, Antineoplastic; Antihypertensive Agents; Bleomycin; Bosentan; Collagen; Connective Tissue Growth Factor; Disease Models, Animal; Hemodynamics; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Lung; Male; Physical Conditioning, Animal; Pulmonary Fibrosis; Rats; Rats, Wistar; Sulfonamides; Time Factors | 2010 |
Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Administration, Oral; Animals; Antihypertensive Agents; Blood Pressure; Bosentan; Familial Primary Pulmonary Hypertension; Heart Ventricles; Hemodynamics; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Monocrotaline; Piperazines; Pulmonary Artery; Purines; Rats; Sildenafil Citrate; Sulfonamides; Sulfones; Vasodilator Agents | 2010 |
Bosentan attenuates right ventricular hypertrophy and fibrosis in normobaric hypoxia model of pulmonary hypertension.
Topics: Animals; Antihypertensive Agents; Bosentan; Collagen; Disease Models, Animal; Endothelin Receptor Antagonists; Endothelin-1; Fibrosis; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Hypoxia; Male; Myocardium; Protein Isoforms; Protein Kinase C; Rats; Rats, Sprague-Dawley; Signal Transduction; Sulfonamides; Ventricular Dysfunction, Right | 2011 |
Nonspecific endothelin-receptor antagonist blunts monocrotaline-induced pulmonary hypertension in rats.
Topics: Animals; Antihypertensive Agents; Bosentan; Cardiac Output; Endothelin Receptor Antagonists; Endothelin-1; Hemodynamics; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Lung; Male; Monocrotaline; Neovascularization, Pathologic; Organ Size; Poisons; Pulmonary Circulation; Rats; Rats, Sprague-Dawley; Sulfonamides | 1997 |